lgibson. By continuing to use our service, you agree to our use of cookies. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and. 5% workforce reduction. 1. Theratechnologies (TSX:TH)has indicated that Trogarzo did not meet its primary endpoints in its IM method study. TH | September 26, 2023. (“Theratechnologies”) with the Securities and Exchange Commission (the. Story. 1300 (+9. The Montreal-based biopharmaceutical company's consolidated net revenues for fourth quarter 2020 are expected to be between US$18. (TSX: TH) (NASDAQ: THTX) (Theratechnologies), a biopharmaceutical company focused on the. Theratechnologies Inc. Stockhouse. This news release constitutes a “designated news release” for the purposes of the Company’s. THERATECHNOLOGIES INC. Stockhouse. The company’s previously announced offering was conducted by a syndicate of underwriters, including companies such as Canaccord Genuity. Headquartered in Montreal, Theratechnologies is a biotech company that develops innovative therapies for unmet medical needs in HIV, oncology, and NASH, a type of liver disease. The Notes were issued under a trust indenture dated as of June 19, 2018, by and among Theratechnologies and Computershare Trust Company of Canada. 35 as of 10:41 a. com 10/16/2023. FY2023 revenue guidance range set between $90 million and $95 million. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical. We also use them to share usage. By continuing to use our service, you agree to our use of cookies. 521. The price has fallen in 7 of the last 10 days and is down by -30. The company was. Company Type For Profit. Theratechnologies stated the primary endpoint measured a 90 per cent confidence interval of the IM injection to IV injection (0. MONTREAL, March 31, 2022 (GLOBE NEWSWIRE) -- Theratechnologies Inc. 1-514-336-7800. FY2023 revenue guidance range set between $90 million and $95 million. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. Cookies are used to offer you a better browsing experience and to analyze our traffic. TH1902 is a first-in-class PDC targeting SORT1, that consists of 2 molecules of docetaxel attached to the TH19P01 peptide via a cleavable succinyl linker. 23) diluted earnings per. Stockhouse. MONTREAL, Aug. Watch list NEW Set a price target alert After Hours Last. stock news by MarketWatch. 35 as of 10:41 a. TH | July 20, 2023. Amount of cash a business has after it has met its financial obligations such as debt and outstanding payments. TH1902 Study Published in Pharmaceutics Demonstrates Inhibition of Human Sortilin (Sort1)-Positive Ovarian and Triple-Negative Breast Cancer Stem-Like Cells and Tumor Growth Sep 13. 30, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. Theratechnologies Announces Certain Preliminary Q3 2023 Financial Highlights. MONTREAL, Nov. 12, 2022 (GLOBE NEWSWIRE) -- Theratechnologies Inc. com. Investor inquiries: Elif McDonald. About TH1902. 16%. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. S. 25 to $1. $30. 514-336-7800. Cookies are used to offer you a better browsing experience and to analyze our traffic. Stockhouse. In collaboration with the University of Manitoba (UM), the company demonstrated that its photodynamic compound (PDC),. Stockhouse. Further. Free cash flow. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. Theratechnologies Inc. Stockhouse. Gary Littlejohn. TH | Complete Theratechnologies Inc. . Join the discussion: Find out what everybody’s saying about this stock on the Theratechnologies Bullboard, and check out the rest of Stockhouse’s stock forums and message boards. MONTREAL, Aug. MONTREAL, June 29, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. Trogarzo® and. MONTREAL, July 12, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. Theratechnologies presented the pre-clinical and clinical data gathered thus far to the SAC, which made recommendations to modify the frequency of administration, selection of tumor types and. We also use them to share usage information with our partners. m. MONTREAL, Feb. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. About Theratechnologies Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. 12, 2022 (GLOBE NEWSWIRE) -- Theratechnologies Inc. 2. Volatility Over Time: TH's weekly volatility has increased from 16% to 25% over the past year. Stockhouse. We currently market. During the last trading day the stock fluctuated 12. (2023-07-21 | TSX:TH) Theratechnologies Announces the Resignation of One of Its Directors, Mr. Follow. is a pharmaceutical company, which engages in addressing medical needs of patients with Human Immunodeficiency Virus (HIV). Theratechnologies Inc. The company reported ($0. In collaboration with the University of Manitoba (UM), the company demonstrated that its photodynamic compound. The reported ($0. Montréal, Québec, Canada . By continuing to use our service, you agree to our use of cookies. (Theratechnologies, or Company) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and. Theratechnologies Appoints New Board Member. By continuing to use our service, you agree to our use of cookies. Stockhouse. Microsoft to invest $500M in Quebec AI economy. com uses cookies on this site. Theratechnologies Receives January 2024 PDUFA Goal Date for Tesamorelin F8 Formulation sBLA. 28 $1. Further. We also use them to share. Theratechnologies Europe Limited 1st Floor, 12 Duke Lane Upper Royal Hibernian Way DUBLIN Dublin 2 Ireland D02 DX07 Phone: +353 1 215 0650Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. “Theratechnologies’ commitment to investors at the beginning of 2023 has been to remain steadfast in delivering on key financial objectives, particularly to achieve positive adjusted EBITDA by the end of the current fiscal year,” said Philippe Dubuc, Senior Vice President and Chief Financial Officer at Theratechnologies. View real-time stock prices and stock quotes for a full financial overview. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. TH | May 19, 2023. $30. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, reported the voting results from its annual meeting of shareholders held today in a virtual-only setting. (THTX) Stock Price, Quote, latest community messages, chart, news and other stock related information. com uses cookies on this site. acts as investment manager. (882) posted 3 minutes ago. com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. com. Canada’s largest financial portal for Canadian small-cap investors is right here at Stockhouse where our Bullboards are a leading forum. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced an update on the plan to amend and optimize the protocol of its Phase 1 oncology. Pour les émetteurs. Investor Relations. MONTREAL, June 22, 2020 (GLOBE NEWSWIRE) -- Theratechnologies Inc. It is the Company’s proprietary. We also use them to share. Stockhouse. Theratechnologies Inc. Theratechnologies inc. The business had revenue of $27. Once expert advice is considered, the Company. (TSX: TH) (NASDAQ: THTX) (Theratechnologies), a biopharmaceutical company focused on the development and commercialization of innovative therapies, announced today that it will report financial results for its second quarter of fiscal 2022 ended May 31 on Thursday, July 14, 2022. Who is Theratechnologies. Theratechnologies (TSX: TH) has posted net revenue estimates for fourth quarter and the full fiscal year ending Nov 30, 2020. 24, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (2022-09-19 | TSX:TH) Theratechnologies to Present at the Cantor Oncology, Hematology & HemeOnc Conference. 10% most volatile stocks in CA Market. However, it did not meet the equivalence limits of 0. znewcar1. [at noodls] - Montreal, Canada - April 17, 2015 - Theratechnologies Inc. T. Senior Director, Investor Relations. MONTREAL, March 07, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. Philippe Dubuc Senior Vice President and Chief Financial Officer Phone: +1-438-315-6608 [email protected]%) S&P 500. 3089 Background: SORT1 is expressed in a variety of tumors when compared to most healthy tissue. Q4 2022 consolidated revenue growth of 14. Theratechnologies is currently developing a platform of proprietary peptides called SORT1+ Technology TM for cancer drug development targeting SORT1. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. We currently market prescription products for people with. Background: Breast and ovarian cancer stem cells (CSC) can contribute to the invasive and chemoresistance phenotype of tumors. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. 2015 Peel Street, 11th Floor Montréal, Québec Canada H3A 1T8 Phone: 514 336-7800 Fax: 514 331-9691. (TSX: TH, Forum) noted that its Q1 2022 consolidated sales grew 20%, supported by 35% growth in sales of EGRIFTA SV formulation. Stockhouse. Further. Cookies are used to offer you a better browsing experience and to analyze our traffic. com uses cookies on this site. FAQ – Utilisateurs de TMX Argent NOUVEAU. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. /NOT FOR DISTRIBUTION TO UNITED STATES OF AMERICA WIRE SERVICES OR DISSEMINATION IN THE UNITED STATES OF AMERICA/. H4S 2B4 (Address of principal executive offices) Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F: Form 20-F ¨ Form 40-F xMain number: 514-336-7800. Theratechnologies has generated ($1. MONTREAL, April 03, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. Theratechnologies’ CFO to Attend Cantor Global Healthcare Conference in New York City Theratechnologies' CFO to Attend Piper Jaffray 31st Annual Healthcare Conference in New York City Stockhouse. La Bourse de Toronto a clôturé en hausse mardi pour une troisième séance consécutive, tandis que les grands indices boursiers américains ont avancé eux aussi. Cookies are used to offer you a better browsing experience and to analyze our traffic. It’s lead investigational peptide drug conjugate linked to docetaxel, a well-established and well-characterized cytotoxic agent used in the. ET. com uses cookies on this site. Focused on small-cap companies and sectors. Cookies are used to offer you a better browsing experience and to analyze our traffic. We changed the address of the Stockhouse website from to stockhouse. MONTREAL, Oct. 5%. (2021-11-23 | TSX:TH) Theratechnologies Announces Renewal of Shelf Prospectus and Registration Statement; At-The-Market Facility to be Extended. com uses cookies on this site. TH Stock Message Board for Investors. 25, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. MONTREAL, Oct. Theratechnologies Inc. On average, they expect the company's stock price to reach $36. ET. com uses cookies on this site. 65 per cent to C$1. THERATECHNOLOGIES INC. 06 million, an increase of 14. Shares of Theratechnologies are up 4. Investor Relations. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. Trogarzo is a CD4-directed post-attachment HIV-1 inhibitor. MONTREAL, Feb. Theratechnologies Inc. (2022-07-27 | TSX:TH) Theratechnologies Announces Closing of Funding of $40 Million Under the Terms of its Credit Agreement Stockhouse. Canadian Commercial-Stage Biopharmaceutical Company Theratechnologies Announces NASDAQ Listing. The Theratechnologies Inc. com uses cookies on this site. Clinical-stage pharmaceutical company Theralase Technologies Inc. (2022-09-12 | TSX:TH) Theratechnologies TH1902 Study Published in Pharmaceutics Demonstrates Inhibition of Human Sortilin (SORT1)-Positive Ovarian and Triple-Negative Breast Cancer Stem-Like Cells and Tumor Growth Fri, 17 Apr 2015 15:08:33 GMT ~ Supreme Court of Canada rules in favour of Theratechnologies. /NOT FOR DISTRIBUTION TO UNITED STATES OF AMERICA WIRE SERVICES OR DISSEMINATION IN THE UNITED STATES OF AMERICA/. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. Forecast to breakeven in 2024 Jul 15. US Headquarters. Market Cap. View Company Info for Free. com. 9 million and US$19. 11, 2021 (GLOBE NEWSWIRE) -- Theratechnologies Inc. Philippe Dubuc Senior Vice President and Chief Financial Officer Phone: +1-438-315-6608 ir@theratech. 4% from the stock's current price. Fri, 17 Apr 2015 15:08:33 GMT ~ Supreme Court of Canada rules in favour of Theratechnologies. Theratechnologies Reports Financial Results for the Third Quarter of Fiscal 2022 and Provides Business Update. Cookies are used to offer you a better browsing experience and to analyze our traffic. com. stock price gained 1. 2% to $21. GUD | Complete Knight Therapeutics Inc. FY2022 revenue. L. Amendment Withdraws the Condition to File HFS Report to the FDA to Access the US$20 Million Second Tranche. Theratechnologies Appoints New Board Member. Montréal, Québec, Canada . By continuing to use our service, you agree to our use of cookies. TH1902 combines Theratechnologies’ proprietary peptide to docetaxel. Non-Profit & Charitable Organizations · United States · <25 Employees. L. By continuing to use our service, you agree to our use of cookies. Theratechnologies Inc. Investor Relations. A high-level overview of Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that President and CEO, Paul Lévesque has issued an open letter to shareholders. 00. There are 102 news items for this page. Theratechnologies, Inc. The company’s marketed products include Egrifta SV is indicated to reduce excess abdominal fat in human immunodeficiency virus (HIV. (THTX) stock. 00 in the next twelve months. Christian Marsolais, Ph. (Translation of registrant’s name into English) 2310 Alfred-Nobel Boulevard . By continuing to use our. C. Philippe Dubuc Senior Vice President and Chief Financial Officer Phone: +1-438-315-6608 ir@theratech. 14, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. Theratechnologies had a negative net margin of 36. Stockhouse. Headquarters. Senior Director, Investor Relations. Vancouver, Canada –– TheNewswire - April 7, 2022 - Teuton Resources Corp. Theratechnologies Reports Financial Results for the Third Quarter and Nine Months of Fiscal 2023 and Provides Business Updates. (TH) has had its first patient receive a dose of TH1902, for the treatment of sortilin positive (SORT1+) solid tumours. Stockhouse. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced receipt of a notification letter (the “Notification Letter. 33. High expression of the sortilin (SORT1) receptor correlates with decreased survival in triple‐negative breast cancer (TNBC) patients. S. Our research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic. Stockhouse. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. About Theratechnologies Theratechnologies (Nasdaq: THTX) (TSX: TH) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical. Stockhouse. Theratechnologies Announces First Patient Dosed in Phase 1 Clinical Trial of TH1902 for Sortilin Positive Solid Tumors. . We also use them to share usage. S. Theratechnologies Inc. Proceeds to Be Used to Redeem All of the Outstanding 5. TH1902 Study Published in Pharmaceutics Demonstrates Inhibition of Human Sortilin (Sort1)-Positive Ovarian and Triple-Negative Breast Cancer Stem-Like Cells and Tumor Growth Sep 13. Stockhouse. 05M. com. UN) today announces steps to strengthen its financial position, including financing and disposition initiatives, and a reduction to its monthly distribution. 10% least volatile stocks in CA Market. (Theratechnologies, or the Company (on a consolidated basis)) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on. By continuing to use our service, you agree to our use of cookies. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today reported business highlights and financial results for the third quarter of fiscal year 2022, ended August. (TSX: TH, Forum) has long been a favourite among Healthcare Bullboard posters who have been following its developments to commercialize innovative therapies. 9 million as at August 31, 2023. 12, 2019 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) today announced that it has applied to list its common shares on NASDAQ. The Notes were issued under a trust indenture dated as of June 19, 2018, by and among Theratechnologies and Computershare Trust Company of Canada. T. July 24 - Heron Therapeutics: Heron is turning to layoffs for the second time in 13 months to cut. MONTREAL, Sept. Cookies are used to offer you a better browsing experience and to analyze our traffic. 13, 2022 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (2020-03-31 | tsx:th) theratechnologies provides business update related to current covid-19 situation Stockhouse. Visit the TSX ETF Investor Centre to access our screener and comparison tool. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. 33 +0. Further. Stockhouse. com uses cookies on this site. Theratechnologies (Nasdaq: THTX) (TSX: TH) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. 31, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. 17. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. m. e. Phone Number 15143319691. Theratechnologies is a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies. FDA for its IV push form of administration of Trogarzo. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that it has decided to pause the enrollment of patients in its Phase 1 clinical trial of. This enduring webinar with Drs Arsalan Shah, Sarah Rowan, Stacey Trooskin, and Juliana Wallace will provide critical updates on specific strategies to improve testing and linkage to care, retention in care, and an overview of guidelines for treatment of HIV and HCV. Theratechnologies is currently developing a platform of proprietary peptides called SORT1+ Technology TM for cancer drug development targeting SORT1 receptors. MONTREAL, Jan. (2022-05-31 | TSX:TH) Theratechnologies Announces New Head of Investor Relations. Theratechnologies Inc. Theratechnologies affirms fiscal 2022 revenue to be in the range of $79 million and $84 million for full fiscal 2022, or growth of the commercial portfolio to be in the range of 13% and 20% as compared to the 2021 fiscal year. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical. com uses cookies on this site. The company reported ($0. com uses cookies on this site. We also use them to share usage. Theratechnologies (TH) and partners contributed $2 million for a research project for a new treatment for metastatic cancer. It engages in addressing medical needs of patients with Human Immunodeficiency Virus (HIV). : Renegotiated Lease to Generate Substantial Annual Savings. Theratechnologies Inc. TO) stock quote, history, news and other vital information to help you with your stock trading and investing. MONTREAL, March 29, 2021 (GLOBE NEWSWIRE) -- Theratechnologies Inc. The SORT1 receptor plays a significant role in protein internalization, sorting and trafficking. 12, 2019 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced it will report financial results and provide a business update for its second. 2 million. Amendment Withdraws the Condition to File HFS Report to the FDA to Access the US$20 Million Second Tranche. (Theratechnologies) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on. Stable Share Price: TH is more volatile than 90% of Canadian stocks over the past 3 months, typically moving +/- 25% a week. View real-time stock prices and stock quotes for a full financial overview. MONTREAL, July 23, 2021 /CNW Telbec/ - Theratechnologies Inc. TH | February 28, 2023. : Nasdaq Theratechnologies Inc. (2020-11-03 | TSX:TH) Theratechnologies Announces Departure of Chief Commercial Officer. com uses cookies on this site. We also use them to share usage. (“Theratechnologies” or “the Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced the strengthening of its global commercial. (TSE:TH) posted its quarterly earnings data on Tuesday, September, 26th. 04) earnings per share (EPS) for the quarter. (THTX) NasdaqCM - NasdaqCM Real Time Price. Theratechnologies Draws Down on US$20 Million Second Tranche Under its Term Loan Facility With Affiliates of Marathon Asset Management. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. MONTREAL, Jan. Wainwright NASH Investor Conference. (2022-02-10 | TSX:TH) Theratechnologies to Announce Financial Results for Its Fourth Quarter and Full Fiscal Year 2021. THTX | Complete Theratechnologies Inc. Theratechnologies Europe Limited 1st Floor, 12 Duke Lane Upper Royal Hibernian Way DUBLIN Dublin 2 Ireland D02 DX07 Phone: +353 1 215 0650 [email protected] (TH) has posted net revenue estimates for fourth quarter and the full fiscal year ending Nov 30, 2020. T. Gain a better understanding of ETFs with our ETF Insights and ETF 101 resource. MONTREAL, Feb. 74M. . (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX) ), a biopharmaceutical company focused on the development. 2015 Peel Street, 11th Floor Montréal, Québec Canada H3A 1T8 Phone: 514 336-7800 Fax: 514 331-9691. 89 $2. (TSX: TH) (NASDAQ: THTX) (Theratechnologies), a biopharmaceutical company focused on the development and commercialization of innovative therapies announced today that it will report its financial results for the second quarter of fiscal 2021 ended May 31, 2021 on Wednesday. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. . Theratechnologies . By continuing to use our service, you agree to our use of cookies. 26, 2022 (GLOBE NEWSWIRE) -- Theratechnologies Inc. S. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. . Theratechnologies Europe Limited 1st Floor, 12 Duke Lane Upper Royal Hibernian Way DUBLIN Dublin 2 Ireland D02 DX07 Phone: +353 1 215 0650 [email protected] Inc. . com uses cookies on this site. 38.